Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of LB-100 With Docetaxel in Solid Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Lixte Biotechnology Holdings, Inc.
Sponsor:
Information provided by (Responsible Party):
Lixte Biotechnology Holdings, Inc.
ClinicalTrials.gov Identifier:
NCT01837667
First received: April 18, 2013
Last updated: February 17, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2016
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)